Neshima is developing life-saving treatments for severe lung diseases using LiFT™, a patented foam-based delivery platform.

LiFT™ enables deep and uniform therapeutic delivery to the alveoli, overcoming the limitations of inhalers, nebulizers, and intravenous treatments.

Our lead applications include a regenerative cell therapy for COPD.

As a cost-effective PoC we are also developing an ICU-delivered antibiotic treatment for antimicrobial-resistant infections.

A fully functional prototype has been tested in large animals.

Neshima is targeting a $10 billion U.S. market with a B2B model.